Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
Healthcare
$3.11 -0.97%
-$0.06 today
- Market cap
- $331.82M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
52W Low $0.52High $8.00
Volume 1.71M
Average 1.24M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$45.79M
FY 2025 · Annual
Investing Cash Flow
-$48.14M
FY 2025 · Annual
Financing Cash Flow
$93.56M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Depreciation & Amortization | 1.26K | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 40.49M | 44.19M | 43.81M | 30.19M | 14.96M |
| Change in Working Capital | (7.86M) | 10.59M | 3.08M | (1.58M) | (3.95M) |
| Accounts Receivables | 79.46K | (426.06K) | 512.43K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.85M | 421.04K | (1.76M) | 624.55K | (2.56M) |
| Other Working Capital | (10.79M) | 10.6M | 4.32M | (2.21M) | (1.39M) |
| Other Non-Cash Items | 1.25M | (1.55M) | 241.16K | (381.66K) | 586.18K |
| Operating Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
| Capital Expenditures | 0 | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (222.98M) | (47.29M) | (90.46M) | (12.08M) | (83.83M) |
| Sales of Investments | 168.86M | 67.03M | 140.92M | 63.64M | 35.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (54.12M) | 19.73M | 50.45M | 51.56M | (48.14M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 185.31M | 42.73M | 0 | 246.75K | 93.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.63M | 2.29M | (98.46K) | (287.09K) | (73.02K) |
| Financing Cash Flow | 187.94M | 45.02M | (98.46K) | (40.34K) | 93.56M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.95M | (39.05M) | (1.3M) | (234.54K) | (360.49K) |
| Free Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$57.4M
+ D&A$0
+ Stock-Based Comp$15.0M
+ Deferred Tax$0
- Working Capital-$3.9M
+ Other Non-Cash$586.2K
= Operating Cash Flow-$45.8M
- Capex$0
= Free Cash Flow-$45.8M
Analysis
FY2025 free cash flow is -$45.8M. FCF conversion is 79.8% of net income. Operating cash flow was -$45.8M, with capex of $0. The largest bridge item is Stock-Based Comp at $15.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 11, 2026 | |
| 8-K | Current report | Sep 8, 2026 |
Does RLMD generate free cash flow?
Relmada Therapeutics, Inc. (RLMD) generated -$45.79M of free cash flow in fiscal 2025.
How much operating cash flow does RLMD produce?
Operating cash flow was -$45.79M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.